Cell and Gene Therapy’s Future a Complex Mix of Promise and Pitfalls

Published on :

At BioBuzz, we’ve written extensively about the promise of cell and gene therapeutics for both patients and the companies developing these revolutionary personalized medicines.

Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid’s Cell Therapy Programs

Published on :

Patented high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology.

5 Questions With… 2020 Recap

5 Questions With 2020
Published on :

In 2020 we introduced a new series titled “5 Questions With…” in an effort to spotlight individuals from across the BioHealth Capital Region and beyond. Providing this platform has allowed us to help share the stories of industry peers and show that there isn’t a single “right” way to becoming an industry success.

Meet Your 2020 BioBuzz Award Winners

Published on :

Today, we are excited to announce the winners of our inaugural BioBuzz Awards. The BioBuzz Awards are a celebration of the exciting and groundbreaking work being done by the BioHealth Capital Region (BHCR) life science community and the individuals that make innovation happen across Maryland, Virginia, and Washington, D.C.

Announcing Finalists for 1st Annual BioBuzz Awards

Published on :

This year, more than ever before, we’ve seen just how important it is for us all to stay connected and work together to build a stronger biotech ecosystem. In the face of great adversity, the biotech community has risen to the challenge and formed new collaborations and partnerships to innovate and rapidly develop new medicines and tools to help us beat this pandemic.

Industry Leaders Identify Key Growth Factors for Cell and Gene Therapy Market

Published on :

At Maryland Lifesciences’ 2020 Bio Innovation Conference, American Gene Technologies (AGT) took center stage. AGT was the virtual event’s diamond sponsor, AGT’s CEO and Founder Jeff Galvin kicked off the event with opening remarks and then hosted several panel discussions, including “Expanding Progress and Opportunities in Gene and Cell Therapy,” which was a highlight of the conference’s second day.

5 Questions with Shruti Abbato, EVP, Business Development, CARMA Cellular Therapies at MaxCyte, Inc.

Published on :

Shruti has 20 years of business development experience in the biotechnology industry. She is currently responsible for building and growing MaxCyte’s CARMA Cell Therapies business. Before MaxCyte, she worked with Celdara Medical, Millendo, Medigene, Deciphera, and Human Genome Sciences. Shruti holds an MBA from the University of Pittsburgh and a BS in Chemical Engineering and Biochemistry from the University of Maryland.